News archive
Showing 695 results
September 2020
-
Media Release
Novartis presents data at ACTRIMS-ECTRIMS on the effects of treatment with Mayzent® (siponimod) studied on disability progression and cognitive processing speed in patients with progressing relapsing multiple sclerosis
Subgroup post hoc analysis of EXPAND reported that Mayzent reduced the risk of cognitive worsening and improved the chance of cognitive improvement at 6 months versus placebo in patients with… -
Media Release
Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates and MRI lesion activity and prolonged time to…
August 2020
-
Media Release
Novartis PARALLAX data provides further evidence of the potential benefit of Entresto® in patients with HFpEF
PARALLAX met one of its co-primary endpoints, showing a significant reduction in NT-proBNP with Entresto (sacubitril/valsartan) compared to individualized medical therapy (IMT) at 12 weeks1; no… -
Media Release
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
-
Media Release
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164… -
Media Release
Novartis launches PsO in the Know podcast series hosted by music icon Cyndi Lauper
-
Media Release
Novartis launches PsO in the Know podcast series hosted by music icon Cyndi Lauper
Podcast to feature 1:1 interviews conducted by Lauper with patients and advocates to address the impact psoriasis (PsO) can have on day-to-day life Guests to include real patient advocates and… -
Media Release
FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
-
Media Release
FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple… -
Media Release
Novartis announces FDA filing acceptance of Xolair® (omalizumab) prefilled syringe for self-administration across all indications
-
Media Release
Novartis announces FDA filing acceptance of Xolair® (omalizumab) prefilled syringe for self-administration across all indications
If approved, Xolair self-administration would offer a more flexible option to help select patients manage their treatment needs Filing acceptance is based on the well-established efficacy and… -
Media Release
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis